Benzodiazepines
Diclazepam
Street names: Chlorodiazepam, 2'-chloro-diazepam
Overdose? Act now. Call emergency services — say "unresponsive, not breathing". Give naloxone for opioid-like signs. Hotlines
⚡What it does
- Long-acting (24–48 h) calm, muscle relaxation
⚠Key risks
- Accumulation with repeated dosing
- Protracted withdrawal
✚Overdose signs
- Sedation
- Impaired coordination
- Slow breathing with mixes
📋Quick facts
Also known asChlorodiazepam, 2'-chloro-diazepam
CategoryBenzodiazepines
Schedule / classProsecutable under Analogue Act (US); banned UK 2017
AppearanceWhite powder or pellets; rarely seen as tablets
Street price~$1–$4 per pellet equivalent
Legal statusAnalogue prosecutions (US); controlled in UK/EU; check locally
Last updated2026-09-12
Sources: EMCDDA, TripSit
Category comparison — Benzodiazepines
| Substance | Class | Top risks | Street price |
|---|---|---|---|
| Diclazepam | Prosecutable under Analogue Act | Accumulation with repeated dosing; Protracted withdrawal | ~$1–$4 per pellet equivalent |
| Diazepam | Schedule IV | Dependence in 2–4 weeks of daily use; Dangerous withdrawal (seizures) — never stop cold turkey | ~$1–$10 per 10 mg tablet |
| Alprazolam (Xanax 2 mg) | Schedule IV | Dependence within weeks; brutal withdrawal (seizures risk); Counterfeit 'bars' increasingly contain fentanyl or bromazolam | ~$2–$10 per 2 mg bar |
| Lorazepam (Ativan 2.5 mg) | Schedule IV | Dependence and withdrawal seizures; Rebound anxiety between doses | ~$1–$5 per 2.5 mg tablet |
| Clonazepam (Rivotril/Klonopin 2 mg) | Schedule IV | Long half-life — dependence builds silently; Withdrawal can last months | ~$1–$5 per 2 mg tablet |
| Nitrazepam (Nipam 5 mg) | Schedule IV | Morning 'hangover' impairment; Dependence and falls in older users | ~$1–$4 per 5 mg tablet |
Street prices are regional estimates. Potency and cuts vary constantly — see our pressed pill guide.
Spotted wrong or outdated info?
Profiles are reviewed against NIDA/DEA/EMCDDA sources. See something off? Submit a correction — it goes straight to our editorial queue.